For the last year and a half, Side Effects Software had been developing a web-based marketplace for highly-customizable 3D content. Similar to Apple’s App Store or Android’s Market, the company’s Orbolt™ Smart Asset Store is an application marketplace where digital artists can purchase smart 3D assets. Entering the e-commerce marketplace for the first time meant the company faced a number of unique challenges. They turned to Yeleiny through Mitacs-Accelerate for web performance expertise.
By 2020, it is estimated that diabetes will cost the Canadian healthcare system $16.9 billion a year. In response, Calgary-based Orpyx Medical Technologies is developing a product that is garnering the attention of the diabetes technology community. The SurroSense Rx is a pressure sensitive insole that relays plantar pressure information to a wristwatch, notifying the user when damage is being done to their feet so that behavior can be modified to avoid complications.
Over the course of his Accelerate internship Zaifman, a postdoctoral fellow at the Chemistry department of the University of British Columbia, partnered with AlCana, a Vancouver biotechnology company developing lipid nanoparticles, which show great potential as a new means for the targeted delivery of therapeutics.
One of the most talked-about biomedical breakthroughs of 2010, this new development offers hope to sufferers of blood and immunological diseases, such as leukemias, who are often unable to find a suitable donor.
“Ideally, under further development, we hope to be able to grow mature blood cells for patients from their own skin, lessening the likelihood of rejection,” Eva said.